Developing advanced techniques for synthesizing and analyzing new drugs
Acquisition of a Supercritical Fluid Chromatography Mass Spectrometer System
['FUNDING_OTHER'] · UNIVERSITY OF WISCONSIN-MADISON · NIH-10852553
This study is all about getting a new high-tech machine to help scientists at the University of Wisconsin-Madison create and understand new medicines better, which could lead to more effective treatments for various health issues.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF WISCONSIN-MADISON (nih funded) |
| Locations | 1 site (MADISON, UNITED STATES) |
| Trial ID | NIH-10852553 on ClinicalTrials.gov |
What this research studies
This research focuses on acquiring a state-of-the-art chromatography mass spectrometer system to enhance the characterization of novel molecules synthesized at the University of Wisconsin-Madison. The system will support various projects aimed at addressing critical biological questions and challenges in drug synthesis. Researchers will utilize advanced techniques to develop new strategies for creating complex organic molecules and small-molecule therapeutics, which could lead to more effective medications. The work involves collaboration among multiple research groups, each contributing unique methodologies to improve drug discovery and development.
Who could benefit from this research
Good fit: Ideal candidates for benefiting from this research include individuals with conditions that could be treated by new pharmaceuticals developed through these advanced synthesis techniques.
Not a fit: Patients with conditions that are not addressed by the specific drugs being developed in this research may not receive any benefit.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective and affordable medications for patients.
How similar studies have performed: Other research has shown success with similar advanced drug synthesis techniques, indicating a promising potential for breakthroughs in pharmaceutical development.
Where this research is happening
MADISON, UNITED STATES
- UNIVERSITY OF WISCONSIN-MADISON — MADISON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: HEINS, SPENCER — UNIVERSITY OF WISCONSIN-MADISON
- Study coordinator: HEINS, SPENCER
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.